A biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer - Favrille, Inc. (Nasdaq: FVRL) – recently announced that the Data Monitoring Committee (DMC) have already completed its prospectively planned interim analysis of a secondary endpoint in the first 233 patients enrolled in the Company's ongoing pivotal, placebo-controlled Phase 3 clinical trial of FavId® following Rituxan® induction therapy in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).
The interim analysis showed a high percentage of patients converted to complete remission over time. The objective response rate (ORR) was first assessed eight weeks following Rituxan induction treatment, at which time it was 64%, with 18% of patients in complete remission.
The best response rate was assessed at three-month intervals and ORR was shown to increase to 70%, with 46% of patients in complete remission. Treatment with FavId or placebo was initiated after the first response assessment.
The DMC indicated that this prospectively planned interim analysis did not demonstrate a statistically significant difference between treatment and control groups in the secondary endpoint of response improvement.
FavId® is Favrille’s patient-specific, active immunotherapy being developed initially for follicular B-cell NHL that is based on unique genetic information extracted from a patient's tumor.
As defined by the American Cancer Society, Non-Hodgkin's lymphoma (NHL) is a cancer of B or T cells in the lymph system and is one of the fastest-growing causes of cancer mortality and the sixth leading form of cancer death in the United States.
Find more about the clinical data from the press release.
Comment Preview